---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036811"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:07:06.812594+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences reports FY2023 net loss $76.4M; Phase 3 CoMpass trial enrolling with FDA SPA

## Summary
- Cash and equivalents $226.2M as of Dec 31, 2023; expected to fund operations into H2 2026.
- Net loss $22.1M Q4 2023 and $76.4M full year 2023 vs $16.6M and $58.8M prior year.
- R&D expenses $65.2M for FY2023, up from $42.2M due to Phase 3 start and manufacturing costs.
- Global Phase 3 CoMpass trial for small choroidal melanoma actively enrolling under FDA SPA; Phase 2 showed 80% tumor control, 90% vision preservation.
- Phase 1 bladder cancer trial ongoing; data expected mid-2024; first patient showed complete response after single dose with light activation.

## SEC filing metadata
- accession: 0000950170-24-036811
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017024036811/0000950170-24-036811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017024036811/aura-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036811
- JSON: https://secwatch.observer/filing/0000950170-24-036811.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036811.txt

## Key facts
- Earnings Releases
  Aura Biosciences, Inc. reported financial results for fourth quarter and year ended December 31, 2023.
  - Period: fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 27, 2024, Aura Biosciences, Inc., issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017024036811/0000950170-24-036811-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.